All News
📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved
substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52.
-PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52.
Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9
Links:
Adela Castro AdelaCastro222 ( View Tweet)
BE MOBILE 1 & 2: Bimekizumab resulted in improvement of SIJ MRI inflammation & structural lesions particularly after 16 wks of treatment and continued on until wk. 52.
Supports addtl evidence of BKZ's winning streak in #axSpA
@RheumNow #ACR24 abs1757 https://t.co/EUntQIuQC8
sheila RHEUMarampa ( View Tweet)
A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA.
@RheumNow
https://t.co/ospR0qEIsd
Akhil Sood MD AkhilSoodMD ( View Tweet)
Smoking and Rx progression in PsA?
-Prospective Canadian cohort of 1736 PsA pts.
-Older age, BL SJC, dactylitis, erosions and high ESR were associated with Rx progression.
🚨Cigarette smoking did not appear to be associated with the Rx progression in PsA.
Abst#1436 #ACR24… https://t.co/J2IogqOlx8 https://t.co/U6SRmbOE6o
Links:
Adela Castro AdelaCastro222 ( View Tweet)
This study by Dr. UGazel et al shows that cervical DISH in SpA is similar to the general population.
Of note, HLAB27+ axSpA pts had more DISH while PsA pts had DISH if they were HLaB27(-)
@RheumNow #ACR24 abs1447 https://t.co/GtcvxVSb8B
sheila RHEUMarampa ( View Tweet)
Gonzalez Molina et al. MANHATTAN observational study. In PsA after 1st TNFi failure should we use guselkumab or 2nd TNFi? Guselkumab slightly better persistence, DAPSA, and improvements in joint counts. @RheumNow #ACR24 Abstr#1469 https://t.co/X3TMCVys6B https://t.co/vvkUYbzVDq
Links:
Richard Conway RichardPAConway ( View Tweet)
Kharouf et al. Secondary biologic failure in PsA common - 36% over 5 years. Predictors - higher baseline SJC HR 1.39 and PASI HR 1.14. TNFi did better, HR 0.40, esp golimumab - but ?this as often used as first bDMARD? @RheumNow #ACR24 Abstr#1455 https://t.co/ET0WX6tKMr https://t.co/iVcCkM0hu3
Links:
Richard Conway RichardPAConway ( View Tweet)
Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy
Links:
Richard Conway RichardPAConway ( View Tweet)
Gottlieb et al. TYK2i Zasocitinib in PsA. 12 week phase 2 RCT. Skin responses and MDA all favour zasocitinib but maybe not fantastic? PASI75 46%, PASI90 37%, PASI100 26%. MDA in photo. @RheumNow #ACR24 Abstr#1477 https://t.co/iX5iriESV2 https://t.co/RkEmcAZ80x
Links:
Richard Conway RichardPAConway ( View Tweet)
Getting more data on using deucravacitinib for PsO/PsA manifestations
Impressive effect on scalp psoriasis (which often means a lot to patients)
Given how safe it is, it's increasingly tempting to use more of it in mild-mod PsA
#ACR24 PSORIATYK SCALP trial ABST1137 @RheumNow https://t.co/vxS3RSlIN0
David Liew drdavidliew ( View Tweet)
Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR)
-bDMARD naïve had less SJC at baseline
-In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time.
#ACR24 @RheumNow https://t.co/zwxsSbga7c
Adela Castro AdelaCastro222 ( View Tweet)
Findings from Abstr#1436 reveal that cigarette smoking is not positively associated with radiographic progression in psoriatic arthritis (PsA). Current and past smokers showed a longer time to joint damage progression. This suggests a complex relationship that warrants further… https://t.co/ERsAKoivA4
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Are biosimilar multi-switches an issue?
real world data: DANBIO 🇩🇰
biosimilar to biosimilar switch
having already had a switch prior ('previous ADAo') did not increase cessation
The risk of biosimilar switching on immunogenicity is greatly overstated
#ACR24 ABST1000 @RheumNow https://t.co/1yAfZrrNd0
David Liew drdavidliew ( View Tweet)
#1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT
➡️n=290, randomised to PBO, 5/15/30mg gps
💥30mg group
📉 Rapid skin improvement @ Wk 2
➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004)
🛟Well tolerated
⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains
#ACR @RheumNow https://t.co/5GusMlVkQ4
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Exciting early data for new highly selective TYK2i zasocitinib
Improved PASI skin scores (though not as much as IL23i...)
Funky skin-related adverse events at higher doses, not sure what to make of that?
#ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh
Links:
Mike Putman EBRheum ( View Tweet)
T2T approaches in early PsA:
-STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injection) vs SoC (MTX25+80mg steroid injection)
-At week 12, 38% pts on SEC vs
17% on SoC achieved ACR50. Also did better on MDA & PASI.
-No significant… https://t.co/MflI3d0FqV https://t.co/RjnzeaTyQK
Links:
Adela Castro AdelaCastro222 ( View Tweet)
#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai
💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%)
⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai.
🔴Durable therapy ❓better outcomes
#ACR @RheumNow https://t.co/LfA3WygNVq
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data
https://t.co/86J4HWKeIv
@RheumNow #ACR24 https://t.co/QYqj5rKHIH
Links:
Eric Dein ericdeinmd ( View Tweet)
Does psoriasis (Pso) affect radiographic progression in ankylosing spondylitis (AS)?
A study comparing radiographic spine assessment in AS patients with and without Pso reveals no significant differences in structural lesions. Male gender is a key factor in structural… https://t.co/z34FjHtjEJ
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#1456
💥In a real-world UK PsA cohort, 25% had joint erosion @ diagnosis
➡️Mean disease duration 34mo. @ diagnosis
➡️Mean disability score = mod. to severe
💥Delay in diagnosis=poor outcomes
‼️Are we doing enough to catch PsA early? ?
🔑Earlier detection key
#ACR @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
